Cryoport (CYRX) Proxy Filing summary

Executive summary

• 2024 was marked by macroeconomic challenges, but cost-cutting and strategic initiatives supported profitability and future growth, with $261 million in cash at year-end and support for a record 701 clinical trials and 19 commercial cell and gene therapies.

• Life Sciences Services grew to over 67% of revenue, driven by double-digit growth in BioStorage/BioServices and commercial cell and gene therapy support, while Life Sciences Products faced market contraction but remained cash flow positive.

• Key innovations included the launch of IntegriCell™ Cryopreservation Solution and Cryoport Express® HV3 Shipping System, enhancing supply chain capabilities for cell and gene therapies.

• A strategic agreement with DHL Group, including the disposition of CRYOPDP, is expected to strengthen logistics in EMEA and APAC, improve margins, and sharpen focus on core markets.

• 2024 revenue reached $228.4 million, with gross margin improving to 45.8% in Q4, and $22 million in annualized savings from cost-reduction initiatives.

Voting matters and shareholder proposals

• Stockholders will vote to elect six directors, ratify Deloitte & Touche LLP as auditor for 2025, approve executive compensation on an advisory basis, and select the preferred frequency of future say-on-pay votes.

• The Board recommends voting for all director nominees, for Deloitte's appointment, for executive compensation, and for annual say-on-pay votes.

Board of directors and corporate governance

• The Board consists of six directors, five of whom are independent, with diverse backgrounds and expertise in life sciences, finance, and global management.

• Committees include Audit, Compensation, Nomination and Governance, and Science and Technology, all chaired by independent directors.

• The Board structure includes a combined Chair/CEO and a Lead Director to ensure independent oversight.

• Policies limit directors to three public company boards and require regular review of board diversity and director commitments.